Paloma Partners’s Avita Medical RCEL Stock Holding History

Paloma Partners’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-27,693	Closed	-$697K	–	2118
2020 Q3	$697K	Buy	+27,693	New	+$690K	0.02%	951

Other funds holding RCEL

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's RCEL Position: Q4 2020 in Review

Paloma Partners sold out of Avita Medical (RCEL) in Q4 2020, closing a stake of 27,693 shares — an estimated $697K sold.

Paloma Partners first reported a position in RCEL in Q3 2020 and held it in 1 quarter. The position peaked at $697K in Q3 2020. 52 funds tracked by Wall St. Rank hold RCEL as of Q4 2020.

Paloma Partners reported no remaining Avita Medical position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 27,693 Avita Medical shares in Q4 2020, an estimated $697K.
Paloma Partners first reported a position in Avita Medical in Q3 2020 and held it in 1 quarter.
Paloma Partners's Avita Medical position peaked at $697K in Q3 2020.
52 funds tracked by Wall St. Rank held Avita Medical as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.